| http://www.w3.org/ns/prov#value | - ety four HIV and HBV co-infected patients (194/226, 85.8%) received dually active antiretroviral therapy against HIV and HBV, including either lamivudine or tenofovir or both, for more than 6 mo as part of their highly active antiretroviral therapy (HAART) for HIV. Treatment with these dually active antiretroviral drugs did not differ between the 2 groups.During the study period, more deaths in th
|
